Employers Tighten GLP-1 Coverage Despite Medicare Access Expansion
A new employer survey reveals that companies are increasingly restricting coverage of GLP-1 obesity drugs through tiered formularies, prior authorizations, and cost-sharing shifts, directly undermining the temporary Medicare GLP-1 Bridge program's aim of expanding access.
The Trump administration's CMS launched the Medicare GLP-1 Bridge program in July 2026, capping out-of-pocket costs at $50 per month for select GLP-1 drugs for Part D enrollees with obesity. Yet a new employer survey shows that private employers are moving in the opposite direction: restricting coverage, increasing cost-sharing, and relying on prior authorization or step therapy to limit use. This is a stark example of how federal policy can be undercut by market dynamics. The administration champions the Bridge as a 'patient-first' move, but without requiring employer plans to maintain coverage or setting minimum standards, the gains remain fragile. The survey data indicate that employer restrictions correlate with rising drug list prices, which the administration has not negotiated down and which the Inflation Reduction Act's Medicare negotiation provisions have only partially addressed for a handful of drugs. The effective result is a two-tier system: temporary federal subsidy for seniors, but continued rationing for working-age adults with commercial insurance.
The humanitarian alternative
Congress should pass the Treat and Reduce Obesity Act to permanently cover anti-obesity medications under Medicare Part D, and the Department of Health and Human Services should use its authority under the Inflation Reduction Act to accelerate price negotiations for GLP-1 drugs. Simultaneously, the Occupational Safety and Health Administration could treat employer wellness programs that deny obesity treatment as discriminatory, and employers should be incentivized through tax credits for maintaining coverage. These steps would ensure the Bridge program doesn't become a temporary fix for a permanent problem.
Falsifiable predictions
What this entry claims will happen, and what data would prove it wrong. The Reckoner revisits these against current reality.
- By January 2027, at least 40% of large employers will have added new utilization management tools (e.g., step therapy, prior authorization) for GLP-1 obesity drugs.
- The average out-of-pocket cost for GLP-1 drugs among privately insured patients will rise by at least 15% in 2027 compared to 2025, even as Medicare beneficiaries see capped costs.
Original source — excerpted
news Healthy Returns: Employers aren't expanding coverage of GLP-1 obesity drugs – many are finding ways around it"A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here t..."